非小细胞肺癌患者血浆和肿瘤组织中p16基因结构异常的研究

目的研究非小细胞肺癌（NSCLC）患者血浆及肿瘤组织中p16基因突变对该病发生、发展和预后的意义。方法应用聚合酶链反应特异性扩增p16基因第2外显子，并用单链构象多态性分析产物突变情况，再与性别、年龄、肿瘤分期等各生物学参数进行相关分析研究。结果32例NSCLC患者血浆中检测到14例p16基因突变（43．75％），而组织中检测到17例（53．12％）。Ⅲ期及Ⅳ期NSCLC患者血浆和组织中p16基因突变率[分别为52．6％（10／19）和63．2％（12／19）]明显高于Ⅰ＋Ⅱ期[分别为30．8％（4／13）和38．5％（5／13）]，差异有统计学意义（P〈0．05）。有淋巴结转移的NSCLC患者血浆和组织中p16基因突变率[分别为52．2％（12／23）和65．2％（15／23）]明显高于无淋巴结转移的患者[均为22．2％（2／9）]，差异有统计学意义（均P〈0．05）。结论血浆中DNAp16基因第二外显子突变在NSCLC中有较高的检出率。血浆p16基因第二外显子突变检出率与肿瘤组织中的突变检出率近似。NSCLC患者血浆中p16基因第二外显子突变与肿瘤临床分期、淋巴结转移有关。检测患者血浆p16基因突变对NSCLC的诊断以及预后评估具有重要价值，方法较为简便。

Plasma and tissue p16 gene mutation in non-small cell lung cancer

Objective To study the significance of plasma and tissue p16 gene mutation in non-small cell lung cancer (NSCLC) patients. Methods Polymerase chain reaction (PCR) amplification exons 2 of p16 gene and single-stranded conformation polymorphism (SSCP) mutation. Results In 32 NSCLC patients, p16 gene muta-tions were found 14 in plasma (43.75%) and 17 in tissue(53.10% ). NSCLC patients with plasma and tissue p16 gene mutation in Ⅲ + Ⅳperiod was significantly higher than that in Ⅰ + Ⅱ period (P>0.05). The rate of Lymph node metastases was significantly higher than that without lymph node metastasis (P>0.05 ). Conclusion Plasma DNA p16 gene mutation in the second exon in NSCLC shows a higher detection rate. The detection rate of plasma DNA p16 gene in the second exon mutation is similar to that of the tumor tissues. The plasma DNA p16 gene in the second exon mutation of NSCLC patients is related with tumor clinical stage and lymph node metastasis. Detection of the plasma p16 gene mutation of NSCLC patients has important value for diagnose and prognosis estimation of NSCLC.